Home
Home

Sprycel

Tackling Cancer: Leukemia's Biggest Current and Upcoming Players

Tackling Cancer: Leukemia's Biggest Current and Upcoming Players
Motley Fool

Can Bristol-Myers Squibb Compete In Immuno-Oncology?

Can Bristol-Myers Squibb Compete In Immuno-Oncology?
Seeking Alpha

Bristol-Myers launches patient management programs for Sprycel patients

Bristol-Myers launches patient management programs for Sprycel patients
The Fly on the Wall

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML
news-medical.net

FDA Warns Bristol Myers Leukemia Drug Could Cause Hypertension

FDA Warns Bristol Myers Leukemia Drug Could Cause Hypertension
FOX Business

Five-Year Follow-Up Data for SPRYCEL® (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant or Intolerant to Gleevec®*

Five-Year Follow-Up Data for SPRYCEL® (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant or Intolerant to Gleevec®*
BusinessWire

News

Bristol-Myers Squibb: Outstanding Pipeline Makes It Most Attractive Among Large Pharmaceuticals
Seeking Alpha

News

FDA expands approval of Bristol-Myers leukemia drug to patients newly diagnosed with disease
Yahoo/AP

News

Bristol-Myers gets drug approvals, awaits more
Yahoo/AP
»

News

Bristol-Myers gets drug approvals, awaits more
Yahoo/AP
»